UAR 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB), supported by FRISBI (ANR-10-INBS-0005-02) and GRAL, financed within the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003)
however approval is not guaranteed and first-movers face high risk USA/Australia & New Zealand/India There may be limited scope to reference GLP-1 through self-substantiated claims, but this carries increased compliance risk For global brands, aligning product positioning, claims and labelling strategies across these differing frameworks will be a key challenge
doi: 10.3389/fgene.2012.00235 Received 04 September 2012 Accepted 16 October 2012 Published 12 November 2012 Volume 3 - 2012 Edited by Jos A
AHAs/BHAs: Acidic environments may reduce peptide activity
Sources: Ahokas EK, Hanstock HG, Kyrlinen H, Ihalainen JK
Individual Variability : Each person may respond differently to peptide therapy